纯氨酸衍生物作为强大的抗癌剂:一个全面的审查
Fiza Farooqui1, Abdul Rahman Khan1, Mohd Arsh Khan1
1Department of Chemistry, Integral University, Lucknow, India.
Future medicinal chemistry
|December 9, 2025
概括
基于纯素的混合分子为开发更安全,更有效的癌症治疗提供了有前途的战略. 这些新型药物向多种癌症途径,可能克服耐药性并减少副作用.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 在全球范围内,癌症是导致死亡的主要原因,化学疗法等现有治疗方法存在局限性.
- 对于既有效又不那么有毒的先进抗癌疗法有着迫切的需要.
- 正在开发多目标药物,以改善治疗结果并最大限度地减少全身副作用.
研究的目的:
- 审查最近在开发用于癌症治疗的基于纯素的混合分子方面的进展.
- 突出这些化合物克服耐药性和向瘤性途径的机制.
- 在设计下一代抗癌药物方面强调纯素支架的治疗潜力.
主要方法:
- 在过去十年中开发的基于纯素的混合分子的综合文献综述.
- 分析了以药物耐药性和瘤性途径抑制为重点的机制研究.
- 在抗癌药物设计中评估纯素支架的治疗相关性和多功能性.
主要成果:
- 纯氨酸类似物,特别是与异环框架相结合时,显示出显著的抗癌活性.
- 基于纯素的混合分子显示出克服多药耐药性的潜力.
- 这些化合物有效地向多个致癌途径,提供多个向的治疗方法.
结论:
- 基于纯素的支架在抗癌药物发现中具有多功能性和治疗意义.
- 基于精氨酸的混合分子的合理设计对于开发更安全,更有效的癌症治疗非常重要.
- 未来的研究应该专注于利用这些支架来制造抗药性和降低毒性药物.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Biosynthesis of Nucleic Acids
924
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
924
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K


